Comparative Risk of Infections with Vedolizumab versus Ustekinumab in Anti-TNF Exposed Pediatric Patients with Inflammatory Bowel Disease

Ning Lyu, Brigham and Woman's hospital and Harvard-MIT center for Regulatory Science, Boston, MA, United States; Michaela Tracy, Boston Children's Hospital, Boston, MA, United States; Sebastian Schneeweiss, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, United States; Timothy Savage, Brigham and Women's Hospital / Boston Children's Hospital, Boston, MA, United States